QIBA SPECT I-123 Biomarker Committee (BC) Call
Friday, November 16, 2018, 9 AM (CT)
Call Summary

In attendance: **RSNA Staff**

John Dickson, PhD (Co-Chair)   Rachid Fahmi, PhD   Nancy Obuchowski, PhD   Joe Koudelik

John Seibyl, MD (Co-Chair)   P. David Mozley, MD   Julie Lisiecki

Moderator: Dr. Seibyl

Profile Work and Timelines
- Dr. Mozley confirmed that the amount of revisions made to version 1.0 justified the development of version 2.0
- The BC's goal is to have an updated Profile draft (version 2.0) by the end of 1Q2019 and plan to re-send the update for a second public comment period of 6 weeks

- Performance requirements have been compiled as a set of checklists developed by Dr. Dickson
  - These checklists have been developed as tools to aid actors and imaging sites with conformance to the Profile
  - The checklists are being used as quality control tools to assess the ability (or practicality/willingness) of actors to perform each of the Profile's performance specifications
  - Results of these feasibility tests will be used to streamline and tighten the Profile performance requirements

- Conformance / feasibility testing is planned to begin in 1Q2019
  - Sites have been selected for feasibility testing
  - A preliminary field test for global practicality may be done prior to the official site tests
  - Checklists will be distributed to sites after public comment officially closes
  - Once initial feasibility testing is complete, the I-123 Profile will be "parked" and made available for use

Parkinson's Progression Markers Initiative (PPMI) Study
- Publicly available data were gathered over the past nine years through this multi-site international study
- A standardized acquisition protocol was used, although standards were not as rigorous as those prescribed by QIBA
- An announcement will be sent to BC members regarding this resource toward the end of January
- There was a slow course of disease progression, with variability both between patients and within the individual patient over the course of the disease
- Drug effects confound assessment of disease progression
- There is phenomenological complexity with regard to the multi-dimensional nature of the disease, the complex and changing clinical picture, and determination of what to track and how to measure milestones
- Dr. Seibyl reviewed data from the Parkinson's Progression Markers Initiative or PPMI Study

Details can be found on the QIBA wiki: http://qibawiki.rsna.org/index.php/I-123_Biomarker_Committee

Next steps: Dr. Seibyl will post changes to the Profile on the QIBA wiki before the next call

Next call: Friday, January 18th at 9 am CT